JP4848358B2 - 非メチル化ＣｐＧモチーフを含むＤＮＡに特異的に結合するタンパク質を用いて原核生物ＤＮＡの濃縮または分離のうち少なくともいずれか一方を行う方法 - Google Patents
非メチル化ＣｐＧモチーフを含むＤＮＡに特異的に結合するタンパク質を用いて原核生物ＤＮＡの濃縮または分離のうち少なくともいずれか一方を行う方法 Download PDFInfo
- Publication number
- JP4848358B2 JP4848358B2 JP2007501210A JP2007501210A JP4848358B2 JP 4848358 B2 JP4848358 B2 JP 4848358B2 JP 2007501210 A JP2007501210 A JP 2007501210A JP 2007501210 A JP2007501210 A JP 2007501210A JP 4848358 B2 JP4848358 B2 JP 4848358B2
- Authority
- JP
- Japan
- Prior art keywords
- dna
- protein
- prokaryotic
- unmethylated
- separation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 129
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 127
- 238000000034 method Methods 0.000 title claims abstract description 96
- 238000000926 separation method Methods 0.000 title claims abstract description 25
- 108020004414 DNA Proteins 0.000 title claims description 248
- 229920002684 Sepharose Polymers 0.000 claims description 27
- 210000001124 body fluid Anatomy 0.000 claims description 25
- 239000000203 mixture Substances 0.000 claims description 25
- 210000004369 blood Anatomy 0.000 claims description 24
- 239000008280 blood Substances 0.000 claims description 24
- 239000010839 body fluid Substances 0.000 claims description 24
- 239000011159 matrix material Substances 0.000 claims description 20
- 125000006850 spacer group Chemical group 0.000 claims description 13
- 239000012634 fragment Substances 0.000 claims description 11
- 239000011859 microparticle Substances 0.000 claims description 9
- 210000004027 cell Anatomy 0.000 claims description 8
- 108020000946 Bacterial DNA Proteins 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 239000012530 fluid Substances 0.000 claims description 7
- 238000000338 in vitro Methods 0.000 claims description 7
- 238000012360 testing method Methods 0.000 claims description 7
- 230000011987 methylation Effects 0.000 claims description 6
- 238000007069 methylation reaction Methods 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 238000001962 electrophoresis Methods 0.000 claims description 4
- 238000005516 engineering process Methods 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 210000002966 serum Anatomy 0.000 claims description 4
- 210000002700 urine Anatomy 0.000 claims description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 239000012528 membrane Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 208000005228 Pericardial Effusion Diseases 0.000 claims description 2
- 238000004378 air conditioning Methods 0.000 claims description 2
- 210000003567 ascitic fluid Anatomy 0.000 claims description 2
- 238000010367 cloning Methods 0.000 claims description 2
- 230000007613 environmental effect Effects 0.000 claims description 2
- 210000004912 pericardial fluid Anatomy 0.000 claims description 2
- 210000004910 pleural fluid Anatomy 0.000 claims description 2
- 210000001179 synovial fluid Anatomy 0.000 claims description 2
- 239000002351 wastewater Substances 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 102000053602 DNA Human genes 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- SYECJBOWSGTPLU-UHFFFAOYSA-N hexane-1,1-diamine Chemical group CCCCCC(N)N SYECJBOWSGTPLU-UHFFFAOYSA-N 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 claims 1
- 230000001131 transforming effect Effects 0.000 claims 1
- 230000027455 binding Effects 0.000 description 39
- 238000003752 polymerase chain reaction Methods 0.000 description 37
- 244000052769 pathogen Species 0.000 description 29
- 238000001514 detection method Methods 0.000 description 27
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 24
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 18
- 150000001413 amino acids Chemical class 0.000 description 16
- 230000001717 pathogenic effect Effects 0.000 description 14
- 239000007983 Tris buffer Substances 0.000 description 13
- VHJLVAABSRFDPM-ZXZARUISSA-N dithioerythritol Chemical compound SC[C@H](O)[C@H](O)CS VHJLVAABSRFDPM-ZXZARUISSA-N 0.000 description 13
- 239000013612 plasmid Substances 0.000 description 13
- 239000000523 sample Substances 0.000 description 13
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 13
- 241000894006 Bacteria Species 0.000 description 11
- 244000052616 bacterial pathogen Species 0.000 description 11
- 239000000872 buffer Substances 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 108020004465 16S ribosomal RNA Proteins 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 238000005119 centrifugation Methods 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- 230000014509 gene expression Effects 0.000 description 8
- 230000000813 microbial effect Effects 0.000 description 8
- 229920000936 Agarose Polymers 0.000 description 7
- 230000003321 amplification Effects 0.000 description 7
- 238000003199 nucleic acid amplification method Methods 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 239000007858 starting material Substances 0.000 description 7
- 239000000499 gel Substances 0.000 description 6
- 238000007857 nested PCR Methods 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 6
- 150000007523 nucleic acids Chemical class 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 230000003115 biocidal effect Effects 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 238000010828 elution Methods 0.000 description 5
- 229960000789 guanidine hydrochloride Drugs 0.000 description 5
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 4
- 101710096438 DNA-binding protein Proteins 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 241000194017 Streptococcus Species 0.000 description 4
- 244000309466 calf Species 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 230000009870 specific binding Effects 0.000 description 4
- 210000001541 thymus gland Anatomy 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102100036168 CXXC-type zinc finger protein 1 Human genes 0.000 description 3
- 230000004568 DNA-binding Effects 0.000 description 3
- 101000947157 Homo sapiens CXXC-type zinc finger protein 1 Proteins 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 102000023732 binding proteins Human genes 0.000 description 3
- 108091008324 binding proteins Proteins 0.000 description 3
- 238000009640 blood culture Methods 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 238000007834 ligase chain reaction Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 2
- 238000007399 DNA isolation Methods 0.000 description 2
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108010058683 Immobilized Proteins Proteins 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- -1 agarose Chemical class 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000003578 bacterial chromosome Anatomy 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000012149 elution buffer Substances 0.000 description 2
- 230000009144 enzymatic modification Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 101710103504 CXXC-type zinc finger protein 1 Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108091029523 CpG island Proteins 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- 108010063593 DNA modification methylase SssI Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241001625930 Luria Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101710085938 Matrix protein Proteins 0.000 description 1
- 101710127721 Membrane protein Proteins 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 101150102573 PCR1 gene Proteins 0.000 description 1
- 239000002262 Schiff base Substances 0.000 description 1
- 150000004753 Schiff bases Chemical class 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 108020005719 Species specific proteins Proteins 0.000 description 1
- 102000007397 Species specific proteins Human genes 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 241000194042 Streptococcus dysgalactiae Species 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- PYVNHBWAEAENNL-UHFFFAOYSA-N azane;hexane Chemical compound N.N.CCCCCC PYVNHBWAEAENNL-UHFFFAOYSA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000007924 bacterial virulence factor Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 230000008081 blood perfusion Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000003196 chaotropic effect Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003302 ferromagnetic material Substances 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000005291 magnetic effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000007769 metal material Substances 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 108010009719 mutanolysin Proteins 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 238000013492 plasmid preparation Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000005373 porous glass Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000003751 purification from natural source Methods 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000002683 reaction inhibitor Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000012502 risk assessment Methods 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 125000005624 silicic acid group Chemical group 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229940115920 streptococcus dysgalactiae Drugs 0.000 description 1
- 108010075210 streptolysin O Proteins 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 108091006106 transcriptional activators Proteins 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
- C12N15/1006—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102004010928.1 | 2004-03-05 | ||
| DE200410010928 DE102004010928B4 (de) | 2004-03-05 | 2004-03-05 | Protein zur Bindung prokaryonter DNA sowie Verfahren zur Trennung und Anreicherung prokaryonter DNA |
| DE200510001889 DE102005001889B4 (de) | 2005-01-14 | 2005-01-14 | Verfahren zur Steigerung der Bindungskapazität und -effizienz eines Proteins, das nicht methylierte CPG-Motive enthaltende DNA spezifisch bindet |
| DE102005001889.0 | 2005-01-14 | ||
| PCT/EP2005/002198 WO2005085440A1 (de) | 2004-03-05 | 2005-03-02 | VERFAHREN ZUR ANREICHERUNG UND/ODER ABTRENNUNG VON PROKARYONTER DNA MITTELS EINES PROTEINS, DAS NICHT-METHYLIERTE CpG-MOTIVE ENTHALTENDE DNA SPEZIFISCH BINDET |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007525982A JP2007525982A (ja) | 2007-09-13 |
| JP2007525982A5 JP2007525982A5 (enExample) | 2009-05-21 |
| JP4848358B2 true JP4848358B2 (ja) | 2011-12-28 |
Family
ID=34921210
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007501210A Expired - Fee Related JP4848358B2 (ja) | 2004-03-05 | 2005-03-02 | 非メチル化ＣｐＧモチーフを含むＤＮＡに特異的に結合するタンパク質を用いて原核生物ＤＮＡの濃縮または分離のうち少なくともいずれか一方を行う方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8481262B2 (enExample) |
| EP (1) | EP1723233B1 (enExample) |
| JP (1) | JP4848358B2 (enExample) |
| AT (1) | ATE554167T1 (enExample) |
| CA (1) | CA2558515C (enExample) |
| DK (1) | DK1723233T3 (enExample) |
| ES (1) | ES2384571T3 (enExample) |
| WO (1) | WO2005085440A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE50207801D1 (de) | 2002-09-18 | 2006-09-21 | Sirs Lab Gmbh | Verfahren zum Nachweis prokaryontischer DNA |
| DE202005009490U1 (de) * | 2005-06-16 | 2006-10-19 | Sirs-Lab Gmbh | Vorrichtung zur Anreicherung/Abtrennung von nicht-methylierte CpG-Motive enthaltender DNA |
| JP5246726B2 (ja) | 2006-10-05 | 2013-07-24 | 株式会社ジャパンディスプレイウェスト | シフトレジスタ回路および表示装置 |
| DE102007041864B4 (de) * | 2007-09-04 | 2012-05-03 | Sirs-Lab Gmbh | Verfahren zum Nachweis von Bakterien und Pilzen |
| US9063130B2 (en) | 2007-09-11 | 2015-06-23 | Kaneka Corporation | Nucleic acid detection method and nucleic acid detection kit |
| US20090137024A1 (en) * | 2007-11-28 | 2009-05-28 | Canon U.S. Life Sciences, Inc. | Method of Separating Target DNA from Mixed DNA |
| AT509622A1 (de) | 2010-04-08 | 2011-10-15 | Greiner Bio One Gmbh | Verfahren und kit zur trennung viraler und prokaryontischer von eukaryontischen nukleinsäuren |
| DE102012219142B4 (de) * | 2012-10-19 | 2016-02-25 | Analytik Jena Ag | Verfahren zum Trennen, Erfassen oder Anreichern von unterschiedlichen DNA-Spezies |
| DE102012021146A1 (de) | 2012-10-25 | 2014-05-15 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Methode zur spezifischen Isolation von Nukleinsäuren |
| WO2016034405A1 (en) | 2014-09-03 | 2016-03-10 | Siemens Aktiengesellschaft | A process for separation of prokaryotic dna from eukaryotic dna in a whole blood sample |
| WO2020216966A1 (en) * | 2019-04-26 | 2020-10-29 | Thermo Fisher Scientific Baltics Uab | Isolated nucleic acid binding domains |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002034565A (ja) * | 2000-07-19 | 2002-02-05 | Japan Science & Technology Corp | 細菌ｄｎａを特異的に認識する受容体タンパク質 |
| WO2004003010A2 (en) * | 2002-07-01 | 2004-01-08 | Inpharmatica Limited | Nuclear hormone receptor ligano-binding domain containing protein |
| JP2005538737A (ja) * | 2002-09-18 | 2005-12-22 | ジルス−ラプ ゲーエムベーハー | 原核生物ｄｎａを濃縮する方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| CA2224492A1 (en) * | 1995-07-28 | 1997-02-13 | Michael E. T. I. Boerrigter | A method of and test kit for mutagenesis testing |
| AU7680300A (en) * | 1999-08-18 | 2001-03-13 | Fraunhofer-Gesellschaft Zur Forderung Der Angewandten Forschung E.V. | Human dna sequences |
| SE0201257D0 (sv) * | 2002-04-25 | 2002-04-25 | Medical Invest In Sweden Ab | Improved Separation |
| GB0423991D0 (en) * | 2004-10-29 | 2004-12-01 | Univ Edinburgh | Applications of nucleic acid fragments |
-
2005
- 2005-03-02 CA CA2558515A patent/CA2558515C/en not_active Expired - Fee Related
- 2005-03-02 ES ES05715667T patent/ES2384571T3/es not_active Expired - Lifetime
- 2005-03-02 JP JP2007501210A patent/JP4848358B2/ja not_active Expired - Fee Related
- 2005-03-02 WO PCT/EP2005/002198 patent/WO2005085440A1/de not_active Ceased
- 2005-03-02 DK DK05715667.1T patent/DK1723233T3/da active
- 2005-03-02 US US10/591,633 patent/US8481262B2/en not_active Expired - Fee Related
- 2005-03-02 AT AT05715667T patent/ATE554167T1/de active
- 2005-03-02 EP EP05715667A patent/EP1723233B1/de not_active Expired - Lifetime
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002034565A (ja) * | 2000-07-19 | 2002-02-05 | Japan Science & Technology Corp | 細菌ｄｎａを特異的に認識する受容体タンパク質 |
| WO2004003010A2 (en) * | 2002-07-01 | 2004-01-08 | Inpharmatica Limited | Nuclear hormone receptor ligano-binding domain containing protein |
| JP2005538737A (ja) * | 2002-09-18 | 2005-12-22 | ジルス−ラプ ゲーエムベーハー | 原核生物ｄｎａを濃縮する方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20080003568A1 (en) | 2008-01-03 |
| US8481262B2 (en) | 2013-07-09 |
| ES2384571T3 (es) | 2012-07-09 |
| WO2005085440A8 (de) | 2005-12-15 |
| WO2005085440A1 (de) | 2005-09-15 |
| ATE554167T1 (de) | 2012-05-15 |
| CA2558515A1 (en) | 2005-09-15 |
| EP1723233B1 (de) | 2012-04-18 |
| CA2558515C (en) | 2013-12-03 |
| JP2007525982A (ja) | 2007-09-13 |
| EP1723233A1 (de) | 2006-11-22 |
| DK1723233T3 (da) | 2012-07-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4175670B2 (ja) | 固体相核酸の単離 | |
| US8288115B2 (en) | Method for enriching a prokaryotic DNA | |
| EP2505666B1 (en) | Methods and compositions for enriching either target polynucleotides or non-target polynucleotides from a mixture of target and non-target polynucleotides | |
| JP4848358B2 (ja) | 非メチル化ＣｐＧモチーフを含むＤＮＡに特異的に結合するタンパク質を用いて原核生物ＤＮＡの濃縮または分離のうち少なくともいずれか一方を行う方法 | |
| US20140038241A1 (en) | Genomic enrichment method, composition, and reagent kit | |
| CN111448315B (zh) | 一种Cas蛋白体系分离DNA的方法 | |
| JP2007525982A5 (enExample) | ||
| EP0741141A2 (en) | Method of purifying ologonucleotide from biological samples | |
| DE102004010928B4 (de) | Protein zur Bindung prokaryonter DNA sowie Verfahren zur Trennung und Anreicherung prokaryonter DNA | |
| JPWO2009066502A1 (ja) | 固体支持体 | |
| JP4163307B2 (ja) | ベロトキシンの精製方法 | |
| CN121108268A (zh) | 蛋白分子及其在鉴定多种血清型的禽致病性大肠杆菌中的应用 | |
| CN116804196A (zh) | 一种用于检测hcmv病毒的核酸适配体、试剂盒及应用 | |
| CN115927244A (zh) | 一种基于微流控技术的单细胞ChIP-seq文库的构建方法 | |
| JP2006042743A (ja) | 細菌の回収方法 | |
| JP2006246732A (ja) | 核酸精製用支持体および精製方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070822 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20071226 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090403 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20101102 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110131 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110607 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110826 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110927 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20111017 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20141021 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20141021 Year of fee payment: 3 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20141021 Year of fee payment: 3 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |